Document is current
Any future updates will be listed below
-
Authors
Kar, Siddhartha P. https://orcid.org/0000-0002-2314-1426
Quiros, Pedro M. https://orcid.org/0000-0002-7793-6291
Gu, Muxin
Jiang, Tao
Mitchell, Jonathan
Langdon, Ryan
Iyer, Vivek
Barcena, Clea
Vijayabaskar, M. S.
Fabre, Margarete A.
Carter, Paul
Petrovski, Slavé
Burgess, Stephen https://orcid.org/0000-0001-5365-8760
Vassiliou, George S. https://orcid.org/0000-0003-4337-8022
-
Funding
Funding for this research was provided by:
Leukemia and Lymphoma Society (RTF6006-19)
Wellcome Trust (WT098051, WT098051, 204623/Z/16/Z)
Research Councils UK (MR/T043202/1)
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Miguel Servet Program (CP20/00130))
Cancer Research UK (C18281/A29019)
British Heart Foundation
DH | National Institute for Health Research (BRC-1215-20014)
- License Information
-
More Information
Article History
Received: 19 October 2021
Accepted: 6 June 2022
First Online: 14 July 2022
Competing interests
: G.S.V. is a consultant to STRM.BIO and holds a research grant from AstraZeneca for research unrelated to that presented here. J.M. and S.P. are current employees and/or stockholders of AstraZeneca. The remaining authors declare no competing interests.
